aspirin has been researched along with Cerebral Small Vessel Diseases in 3 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Cerebral Small Vessel Diseases: Pathological processes or diseases where cerebral MICROVESSELS show abnormalities. They are often associated with aging, hypertension and risk factors for lacunar infarcts (see LACUNAR INFARCTION); LEUKOARAIOSIS; and CEREBRAL HEMORRHAGE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cerebral small vessel disease is characterized by progressive cerebral white matter changes (WMCs)." | 3.11 | Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. ( Cho, SJ; Choi, SH; Choi, YH; Han, HJ; Jeong, JH; Kim, BC; Kim, EJ; Kim, JH; Kim, S; Lee, JH; Lee, JM; Na, DL; Oh, MS; Park, G; Park, HY; Park, KC; Park, KH; Park, KW; Park, SA; Shim, Y; Yoon, B; Yoon, SJ; Youn, YC, 2022) |
| "Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels." | 2.82 | Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. ( Chiang, LLW; Hafdi, M; Kwan, J; Myint, PK; Quinn, TJ; Wong, LS, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, BC | 1 |
| Youn, YC | 1 |
| Jeong, JH | 1 |
| Han, HJ | 1 |
| Kim, JH | 1 |
| Lee, JH | 1 |
| Park, KH | 1 |
| Park, KW | 1 |
| Kim, EJ | 1 |
| Oh, MS | 1 |
| Shim, Y | 1 |
| Lee, JM | 1 |
| Choi, YH | 1 |
| Park, G | 1 |
| Kim, S | 1 |
| Park, HY | 1 |
| Yoon, B | 1 |
| Yoon, SJ | 1 |
| Cho, SJ | 1 |
| Park, KC | 1 |
| Na, DL | 1 |
| Park, SA | 1 |
| Choi, SH | 1 |
| Kwan, J | 1 |
| Hafdi, M | 1 |
| Chiang, LLW | 1 |
| Myint, PK | 1 |
| Wong, LS | 1 |
| Quinn, TJ | 1 |
| Bouasquevisque, DS | 1 |
| Benavente, OR | 1 |
| Shoamanesh, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
| LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.[NCT03451591] | Phase 2/Phase 3 | 363 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
| Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White[NCT00847860] | Phase 4 | 200 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Stroke and Coated-Platelets - A Translational Research Initiative[NCT04698031] | Phase 4 | 152 participants (Anticipated) | Interventional | 2022-03-30 | Recruiting | ||
| Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)[NCT03061006] | Phase 4 | 101 participants (Actual) | Interventional | 2017-04-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aspirin and Cerebral Small Vessel Diseases
| Article | Year |
|---|---|
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antiplatelet Therapy in Cerebral Small Vessel Disease.
Topics: Aspirin; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Clopidogrel; Drug Therapy, Combination | 2019 |
1 trial available for aspirin and Cerebral Small Vessel Diseases
| Article | Year |
|---|---|
Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Double | 2022 |